- Home
- CAPT vs PHGE Comparison
CAPT vs PHGE Comparison
Compare CAPT & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPT
- PHGE
- Stock Information
- Founded
- CAPT 2005
- PHGE 2015
- Country
- CAPT South Korea
- PHGE Israel
- Employees
- CAPT N/A
- PHGE N/A
- Industry
- CAPT Blank Checks
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- CAPT Finance
- PHGE Health Care
- Exchange
- CAPT Nasdaq
- PHGE Nasdaq
- Market Cap
- CAPT 12.4M
- PHGE 13.3M
- IPO Year
- CAPT N/A
- PHGE N/A
- Fundamental
- Price
- CAPT $0.53
- PHGE $0.60
- Analyst Decision
- CAPT
- PHGE Strong Buy
- Analyst Count
- CAPT 0
- PHGE 2
- Target Price
- CAPT N/A
- PHGE $13.50
- AVG Volume (30 Days)
- CAPT 772.1K
- PHGE 120.2K
- Earning Date
- CAPT 01-01-0001
- PHGE 04-02-2025
- Dividend Yield
- CAPT N/A
- PHGE N/A
- EPS Growth
- CAPT N/A
- PHGE N/A
- EPS
- CAPT N/A
- PHGE N/A
- Revenue
- CAPT $17,389,944.00
- PHGE N/A
- Revenue This Year
- CAPT N/A
- PHGE N/A
- Revenue Next Year
- CAPT N/A
- PHGE N/A
- P/E Ratio
- CAPT N/A
- PHGE N/A
- Revenue Growth
- CAPT 84.70
- PHGE N/A
- 52 Week Low
- CAPT $0.37
- PHGE $0.48
- 52 Week High
- CAPT $6.75
- PHGE $4.99
- Technical
- Relative Strength Index (RSI)
- CAPT 49.49
- PHGE 37.84
- Support Level
- CAPT $0.47
- PHGE $0.55
- Resistance Level
- CAPT $0.68
- PHGE $0.69
- Average True Range (ATR)
- CAPT 0.08
- PHGE 0.11
- MACD
- CAPT 0.00
- PHGE -0.02
- Stochastic Oscillator
- CAPT 27.23
- PHGE 8.49
About CAPT Captivision Inc.
Captivision Inc Formerly Glaam Co Ltd is engaged in manufacturing, installing, and selling LED display G-Glass. G-Glass is an integrated ICT product that has the basic characteristics of transparent glass but can display media images at the same time. It implements media images through the glass surface while preserving the features of clear and transparent glass. G-Glass is the world's first IT building material that can be applied to various places where glass is used.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.